A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 641 participants.

Also called NCT01790438

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 641 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01790438
  • EudraCT 2012-003941-13
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Czechia, Germany, Hungary, Mexico, Poland, Puerto Rico, South Korea, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01790438. Randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2018-05-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes
Acronym
IMAGINE 6
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2605541
Intervention (Drug)
Human Insulin NPH
Intervention (Drug)
Oral Antihyperglycemic Medications (OAM)
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01790438
Content hash
c266076a5247a511439add90cf03f8c0d5281266ee717005b32d9a0d61fc351c